Treat severe neurologic symptoms with controlled 3% saline boluses, then prevent overcorrection by separating the immediate symptom target from the 24-hour safety ceiling.
Severe symptomatic hyponatremia: rescue symptoms without overcorrection
The goal is rapid symptom rescue with a small controlled sodium increase—not rapid normalization of the serum sodium.
Seizure, severe confusion/stupor/coma, respiratory compromise or other convincing severe neurologic symptoms attributable to hypotonic hyponatremia warrant immediate hypertonic saline while the cause is investigated.
Use a controlled 3% saline bolus strategy (commonly 100–150 mL over about 10–20 minutes depending on protocol) and repeat if severe symptoms persist, with prompt sodium reassessment. The immediate therapeutic aim is usually a small rise of about 4–6 mmol/L sufficient to reverse life-threatening cerebral edema—not normalization of sodium.
After initial symptom rescue, stop treating to a numeric target and respect correction limits. In chronic/unknown-duration hyponatremia, a conservative ceiling of ≤8 mmol/L in any 24 hours is widely used; patients at very high ODS risk (very low starting sodium, alcoholism, malnutrition, advanced liver disease or severe hypokalemia) warrant an even more conservative 4–6 mmol/L/day strategy.
Caution
A 4–6 mmol/L rise is an initial symptom-rescue target, not permission to continue correcting at that rate. The 24-hour ceiling is a separate safety constraint.
Guideline framework for hypertonic saline, correction limits and overcorrection prevention.
Evidence status
Review metadata not yet recorded.
Status, review dates and guideline versions appear here once editorial metadata is authored for this content.
From urgent 'AEIOU' indication screening and modality selection to vascular access, dosing, and anticoagulation.
From emergent cardiac membrane stabilization to intracellular shifting, elimination, and dialysis triggers.
From primary disorder confirmation and Anion Gap calculation to Winter's compensation, delta ratio, and targeted source control.
From confirming AKI to classifying it by mechanism.
Tonicity assessment, etiologic classification, 3% hypertonic saline bolus protocols, individualized ODS-safe correction limits, DDAVP relowering, DI diagnostics, and evidence-aware hypernatremia correction.
Monro-Kellie doctrine, ICP waveforms (P2>P1, Lundberg A-waves), CPP targets (60–70 mmHg), herniation syndromes, and the 4-tier BTF management protocol.
ARAS neuroanatomy, structural vs toxic-metabolic coma, the comprehensive Coma Exam (pupils, cold calorics, posturing), FOUR score, and CAM-ICU delirium.
Recognition and time-sensitive escalation of care for prolonged or repeated seizures.
Principles of convection vs diffusion, filtration fraction, delivered effluent dosing (20–25 mL/kg/h), Regional Citrate Anticoagulation, and citrate toxicity.
Sepsis-AKI microcirculatory decoupling, KDIGO staging, Furosemide Stress Test (FST), urine microscopy, and the AEIOU dialysis threshold framework.